EpiCareSRT, Sensus Healthcare aim for mobile non-surgical skin cancer treatment service

December 06, 2015

UCB has initiated a Phase III program for epratuzumab in lupus in which 2 trials, EMBODY?? 1 and EMBODY?? 2, will each enroll approximately 780 patients with moderate to severe systemic lupus erythematosus. (Please refer to the Company's press release at www.immunomedics/news_pdf/2010_PDF/PR12142010.pdf for more information).  Results from Cancer and Leukemia Group B's Phase II study combining epratuzumab and rituximab as initial therapy for patients with follicular non-Hodgkin's lymphoma were reported in an oral presentation at the 52nd annual meeting of the American Society of Hematology. (For more information, please refer to the Company's press release at www.immunomedics/news_pdf/2010_PDF/PR12062010a.pdf).


Nycomed has submitted regulatory filings for a Phase II study of the subcutaneous formulation of veltuzumab in patients with rheumatoid arthritis. The trial is expected to begin patient enrollment in the first quarter of calendar year 2011 in the United States while regulatory approval in Europe is pending.

Clivatuzumab tetraxetan

Results updated at the 2011 Gastrointestinal Cancers Symposium indicated that treatments with fractionated yttrium-90-labeled clivatuzumab tetraxetan in combination with gemcitabine extend survival of patients with inoperable, advanced pancreatic cancer. (For more information, please refer to the Company's press release at www.immunomedics/news_pdf/2011_PDF/PR01212011.pdf).


Preliminary results from a Phase I/II study combining milatuzumab with veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma were presented at the 2010 American Society of Hematology annual meeting. (Please refer to the Company's press release at www.immunomedics/news_pdf/2010_PDF/PR12052010.pdf for more information).

SOURCE Immunomedics